Literature DB >> 18647585

Therapeutic options for premature coronary artery disease.

Ameen F Person1, Cam Patterson.   

Abstract

Although cardiovascular disease is commonly recognized as a disease of the elderly, young patients are also at risk for coronary atherosclerosis, which has a devastating impact on their more active lifestyle. In identifying patients at risk for a cardiovascular event, global risk models often fail to assess family history, an important risk factor in patients with premature coronary artery disease (P-CAD). P-CAD refers to the accelerated development of coronary atherosclerosis before age 55 in men and 65 in women, which may be the result of acquired or primary causes. Acquired P-CAD is associated with an underlying medical condition or influencing factor, such as systemic lupus erythematosus or cocaine use, that directly contributes to the rapid progression of coronary atherosclerosis. It is important to evaluate young patients for acquired P-CAD because in many instances treatment may be tailored to the underlying medical condition. Most cases of P-CAD, however, are the result of primary causes involving more complex interactions among genetic, metabolic, and environmental risk factors. Patients with primary P-CAD usually have a family history of coronary disease, suggesting a strong genetic component. With the use of genome-wide association analysis, several chromosome loci have been identified as being linked to the development of coronary atherosclerosis and risk factors. The chromosome 9p21.3 locus, which is the most replicated to date, has provided some insight into the pathologic mechanism of coronary disease. The confirmation and replication of these associations through further study will lead to earlier detection of P-CAD in at-risk patients and a better understanding of the underlying pathologic mechanisms, thereby influencing the development of preventive therapies.

Entities:  

Year:  2008        PMID: 18647585     DOI: 10.1007/s11936-008-0050-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  50 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Substitution of asparagine for aspartic acid at residue 9 (D9N) of lipoprotein lipase markedly augments risk of ischaemic heart disease in male smokers.

Authors:  P J Talmud; S R Bujac; S Hall; G J Miller; S E Humphries
Journal:  Atherosclerosis       Date:  2000-03       Impact factor: 5.162

3.  Young adults with family history of coronary heart disease have increased arterial vulnerability to metabolic risk factors: the Cardiovascular Risk in Young Finns Study.

Authors:  Markus Juonala; Jorma S A Viikari; Leena Räsänen; Hans Helenius; Matti Pietikäinen; Olli T Raitakari
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-04-13       Impact factor: 8.311

4.  Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

Authors:  David E Kelley; George A Bray; F Xavier Pi-Sunyer; Samuel Klein; James Hill; John Miles; Priscilla Hollander
Journal:  Diabetes Care       Date:  2002-06       Impact factor: 19.112

5.  Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients.

Authors:  Omer Karadag; Meral Calguneri; Enver Atalar; Bunyamin Yavuz; Ali Akdogan; Umut Kalyoncu; Sule Apras Bilgen; Necla Ozer; A Ihsan Ertenli; Kenan Ovunc; Sedat Kiraz
Journal:  Clin Rheumatol       Date:  2006-08-15       Impact factor: 2.980

6.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

7.  Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis.

Authors:  J L Goldstein; M S Brown
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

8.  Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Authors:  R G Bakker-Arkema; M H Davidson; R J Goldstein; J Davignon; J L Isaacsohn; S R Weiss; L M Keilson; W V Brown; V T Miller; L J Shurzinske; D M Black
Journal:  JAMA       Date:  1996-01-10       Impact factor: 56.272

9.  Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts.

Authors:  F A Dressler; S Malekzadeh; W C Roberts
Journal:  Am J Cardiol       Date:  1990-02-01       Impact factor: 2.778

10.  Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.

Authors:  Eleftheria Zeggini; Michael N Weedon; Cecilia M Lindgren; Timothy M Frayling; Katherine S Elliott; Hana Lango; Nicholas J Timpson; John R B Perry; Nigel W Rayner; Rachel M Freathy; Jeffrey C Barrett; Beverley Shields; Andrew P Morris; Sian Ellard; Christopher J Groves; Lorna W Harries; Jonathan L Marchini; Katharine R Owen; Beatrice Knight; Lon R Cardon; Mark Walker; Graham A Hitman; Andrew D Morris; Alex S F Doney; Mark I McCarthy; Andrew T Hattersley
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.